Aurobindo Pharma Ltd

Sub-licenses enable manufacturing to take place in India

Geojit Retail Equity Research

It aims to commercialise 50 products in US market over next 12 months

Revenue increased 6.7 per cent to ₹6,407 crore

The product is expected to be launched in Q1 FY24; scrip zooms 6%

BSE, CDSL, RVNL, PC Jeweller, Muthoot Finance, broking stocks, Aurobindo Pharma, NTPC, Adani Power, Adani Wilmar, 3M India, Cummins India, Equitas Bank, Escorts, Eureka Ind, Gati, Godrej Agro, GTL, GTL Infra, Midhani, Minda Corp, Samvardhana Motherson, Piramal Enterprises, Tracxn Technologies, Trent

Amphotericin B Liposome for Injection is expected to be launched by Q4 FY23

Aurobindo Pharma’s shares plunge 6.52% to ₹457.20 on the BSE, while it declined 6.60% to ₹457 at the NSE

Says Aurobindo Pharma’s whole time director P Sharath Chandra Reddy was one the king pins of liquor scam

Aurobindo’s scrip closed down 11.7 per cent to end at ₹478.10 on the BSE on Thursday